Now, using RNA‐seq, whole exome sequencing and clinical data from cancer patients, including several already published cohorts of melanoma patients under immunotherapy, our data indicate RECQL4 as a potentially ‘druggable’ factor associated with an unfavourable anti‐tumour immune response. Here, RECQL4 is linked to cancer.